Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its position in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 17.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,085,281 shares of the company's stock after selling 223,603 shares during the quarter. Dimensional Fund Advisors LP owned 1.33% of Sutro Biopharma worth $3,180,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its stake in Sutro Biopharma by 30.8% during the second quarter. Acadian Asset Management LLC now owns 1,574,958 shares of the company's stock worth $4,613,000 after buying an additional 370,705 shares during the period. Rhumbline Advisers boosted its position in Sutro Biopharma by 23.3% during the 2nd quarter. Rhumbline Advisers now owns 116,099 shares of the company's stock worth $340,000 after purchasing an additional 21,935 shares during the period. Panagora Asset Management Inc. boosted its position in Sutro Biopharma by 15.6% during the 2nd quarter. Panagora Asset Management Inc. now owns 907,503 shares of the company's stock worth $2,659,000 after purchasing an additional 122,299 shares during the period. Bank of New York Mellon Corp increased its holdings in Sutro Biopharma by 47.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 272,719 shares of the company's stock valued at $799,000 after purchasing an additional 88,034 shares in the last quarter. Finally, Virtu Financial LLC raised its position in Sutro Biopharma by 276.7% in the first quarter. Virtu Financial LLC now owns 63,157 shares of the company's stock valued at $357,000 after purchasing an additional 46,391 shares during the period. Hedge funds and other institutional investors own 96.99% of the company's stock.

Sutro Biopharma Trading Up 14.5 %

NASDAQ STRO traded up $0.48 during trading hours on Friday, reaching $3.79. 894,660 shares of the company traded hands, compared to its average volume of 839,119. The stock has a market capitalization of $310.63 million, a PE ratio of -2.02 and a beta of 1.17. Sutro Biopharma, Inc. has a 12 month low of $2.01 and a 12 month high of $6.13. The company has a 50 day moving average of $3.94 and a two-hundred day moving average of $3.93.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.20. Sutro Biopharma had a negative net margin of 73.48% and a negative return on equity of 102.06%. The business had revenue of $25.71 million for the quarter, compared to analysts' expectations of $26.28 million. On average, equities research analysts anticipate that Sutro Biopharma, Inc. will post -2.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $17.00 target price on shares of Sutro Biopharma in a research report on Monday, September 16th. Truist Financial lowered their price objective on shares of Sutro Biopharma from $18.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, August 16th. Piper Sandler reissued an "overweight" rating and set a $11.00 target price on shares of Sutro Biopharma in a research report on Friday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $12.00 price target on shares of Sutro Biopharma in a report on Friday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Sutro Biopharma currently has a consensus rating of "Buy" and a consensus price target of $12.13.

Sutro Biopharma Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.